Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market has been witnessing significant growth in recent years.
Customer preferences: The increasing prevalence of autoimmune diseases and organ transplantations has been driving the demand for immunosuppressants across the world. The rising geriatric population, which is more susceptible to these diseases, along with the advancements in medical technology, has further fueled the growth of this market.
Trends in the market: In the United States, the immunosuppressants market has been witnessing a shift towards generic drugs due to the high cost of branded drugs. The market is also witnessing a trend towards personalized medicine, where drugs are tailored according to the patient's genetic makeup. In Europe, the market is dominated by calcineurin inhibitors, which are used to prevent organ rejection in transplant patients. The Asia Pacific region is expected to witness significant growth in the coming years due to the rising prevalence of autoimmune diseases and organ transplantations in the region.
Local special circumstances: In Japan, the government has been promoting the use of generic drugs to reduce healthcare costs. This has resulted in a shift towards generic immunosuppressants in the country. In India, the market is dominated by cyclosporine, which is used to prevent organ rejection in transplant patients. The high cost of branded drugs has resulted in a significant demand for generic drugs in the country.
Underlying macroeconomic factors: The global immunosuppressants market is expected to witness significant growth in the coming years due to the rising prevalence of autoimmune diseases and organ transplantations across the world. The increasing geriatric population, advancements in medical technology, and rising healthcare expenditure are expected to further fuel the growth of this market. However, the high cost of branded drugs and the increasing availability of generic drugs are expected to restrain market growth in certain regions.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
